Sintilimab Scintillates in First-line Non-squamous NSCLC Sintilimab Scintillates in First-line Non-squamous NSCLC

The investigational immunotherapy shows progression-free survival rates comparable to pembrolizumab when added to standard chemotherapy in non-squamous NSCLC, but mature survival data are awaited.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news